Prognostic Impact of Lateral Pelvic Node Dissection on the Survival of Patients in Low Rectal Cancer Subgroups Based on Lymph Node Size
Koya Hida(Kyoto University Hospital), Mamoru Uemura(Osaka International Cancer Institute), Daisuke Nishizaki(Kyoto University Hospital), Ryosuke Okamura(Kyoto University Hospital), Kenji Kawada(Kyoto University Hospital), Atsuhiko Sumii(Kyoto University Hospital), Seiichiro Yamamoto(National Cancer Centre Japan), Tomonori Akagi(Oita University), Tomohiro Yamaguchi(Japanese Foundation For Cancer Research), Yoshiharu Sakai(The Japanese Society of Gastroenterological Surgery), Shigeki Arizono(Kobe City Medical Center General Hospital), Tsuyoshi Konishi(Japanese Foundation For Cancer Research), Hirotoshi Hasegawa(Tokyo Dental College Ichikawa General Hospital), Masahiko Watanabe(The Japanese Society of Gastroenterological Surgery), Satoshi Morita(Kyoto University), Takashi Akiyoshi(The Japanese Society of Gastroenterological Surgery), Meiki Fukuda(Osaka Red Cross Hospital)
Cited by 24
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2011|713
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer
|International Journal of Clinical Oncology|2015|600